ORPHA:79139
Japanese encephalitis
Publications
24,924
Trials
71
Interventional, condition-specific
Researchers
1,159
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
Japanese encephalitis is an arboviral disease (i.e. a disease due to a virus transmitted by an arthropod).
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019209
- MeSH:D004672
- UMLS:C0014057
- NCIT:C34577
Additional Mondo synonyms (2)
Encephalitis, Japanese · Japanese B encephalitis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
24,924 matched papers (13,833 in last 10 years) Source
- Phenotype characterisedPresent
86 HPO annotations (e.g. Facial grimacing; Distal lower limb muscle weakness; Weakness due to upper motor neuron dysfunction) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPartial
1 EMA designation (none yet with FDA orphan-indication approval) — e.g. purified inactivated Japanese encephalitis SA14-4-2 virus vaccine Source
- Interventional trialPresent
71 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
86
Associated phenotypes · MONDO:0019209
- Facial grimacing
- Distal lower limb muscle weakness
- Weakness due to upper motor neuron dysfunction
- Increased total neutrophil count
- CSF pleocytosis
Showing 5 of 86 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
1
Designation · no FDA orphan-indication approval yet
- EMA purified inactivated Japanese encephalitis SA14-4-2 virus vaccinePrevention of Japanese encephalitis · 24/01/2006 · WithdrawnEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
2
Drugs / clinical candidates · MONDO_0019209
- HUMAN IMMUNOGLOBULIN G·phase 2
- RIBAVIRIN·phase 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
24,924
24,924 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
24,924 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
13,833 in the last 10 years · low confidence
Phrase hits: 24,924 · MeSH hits: 69
Who's working on it?
1,159
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang X10 papers · 2026
National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, China.
Papers in Europe PMC - 02Li X9 papers · 2026
Guangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China.
Papers in Europe PMC - 03Wang Y9 papers · 2026
Key Laboratory of Veterinary Chemical Drugs and Pharmaceutics, Ministry of Agriculture and Rural Affairs, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, China.
Papers in Europe PMC - 04Liu X7 papers · 2026
National Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China.
Papers in Europe PMC - 05Dhanze H6 papers · 2026
Division of Veterinary Public Health, ICAR, Indian Veterinary Research Institute, Izatnagar, India. Electronic address: hdhanze@yahoo.co.in.
Papers in Europe PMC - 06Kumar A6 papers · 2026
Department of Molecular Medicine and Biotechnology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India. dralokkumar03@gmail.com.
Papers in Europe PMC - 07Kumar S6 papers · 2026
Department of Bioscience and Bioengineering, Indian Institute of Technology, Guwahati, Assam, India.
Papers in Europe PMC - 08Li J6 papers · 2026
State Key Laboratory of Genome and Multi-omics Technologies, BGI Research, Shenzhen, China. lijunhua@genomics.cn.
Papers in Europe PMC - 09Zhang L6 papers · 2026
National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, China.
Papers in Europe PMC - 10Wang H5 papers · 2026
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
71
interventional trials for this specific condition
71 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026
71 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 98th percentile).
low confidence · 98th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
71 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06680128·RECRUITING·A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
Not reviewed·Conditions: Japanese Encephalitis Virus Disease·Matched via name phrase
Observational and natural-history studies
7 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06674837·NOT YET RECRUITING·Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus
Not reviewed·Conditions: Japanese Encephalitis·Matched via name phrase
- NCT07358910·RECRUITING·Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Not reviewed·Conditions: Dengue · Chikungunya · Zika Virus Infection · Japanese Encephalitis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 27 · after dedupe 27 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 27 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (27)
- isrctn·ISRCTN61739313·No longer recruiting·Evaluating a single intervention product to protect people in both indoor and outdoor contexts from multiple vector-borne diseases.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98882766·Recruiting·A study of arbovirus-infected individuals that have travelled from outside of the UK
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12240140·No longer recruiting·Assessing optimal timing for childhood vaccines in Nepal
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11643110·No longer recruiting·TyVAC Bangladesh: Typhoid Vaccine Trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN97846634·No longer recruiting·Neurological manifestations of dengue: a comparative study of viral, clinical, pathophysiological and genetic factors
skipped — LLM skipped (--skip-llm)
- ctis·2025-523476-23-00·Authorised·Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) – A phase 2 proof-of-concept, national, multicenter, randomized, double-blind, placebo-controlled clinical study designed to evaluate the efficacy of remdesivir in adult patients hospitalized for TBE
skipped — LLM skipped (--skip-llm)
- ctis·2024-519876-17-00·Authorised·Immune response to intradermally administered Ixiaro in healthy adults
skipped — LLM skipped (--skip-llm)
- ctis·2023-509575-16-00·Authorised, ongoing·Low-Intervention Clinical Trial Evaluating a Novel Cytokine Release Assay for Tick-Borne Encephalitis (TBE) Among Healthy and Immunosuppressed Research Participants
skipped — LLM skipped (--skip-llm)
- ctis·2025-522768-33-00·Authorised, ongoing·Is [18F]-DPA-714 PET a good marker of neuroinflammation in autoimmune encephalitis? (EAI-714)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523146-27-00·Authorised, ongoing·Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.
skipped — LLM skipped (--skip-llm)
- ctis·2024-517653-27-00·Authorised, ongoing·A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants with Advanced Prostate Cancer
skipped — LLM skipped (--skip-llm)
- ctis·2024-514186-18-00·Authorised, ongoing·A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD)
skipped — LLM skipped (--skip-llm)
- ctis·2024-520427-86-00·Authorised, ongoing·Phase I, open-label clinical trial to evaluate the safety and clinical response of repeated-dose intra-arterial infusion of autologous mesenchymal cells in children and adolescents with refractory epilepsies.
skipped — LLM skipped (--skip-llm)
- ctis·2023-507141-28-00·Authorised, ongoing·A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as monotherapy or in combination with other anticancer therapies in adults with advanced solid tumors
skipped — LLM skipped (--skip-llm)
- ctis·2024-515985-16-00·Cancelled·Dexamethasone in Herpes Simplex Virus Encephalitis
Open label Randomized Controlled Trial with an Observer-blinded evaluation at 6 months
skipped — LLM skipped (--skip-llm)
- ctis·2023-504226-18-00·Authorised, recruiting·A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
skipped — LLM skipped (--skip-llm)
- ctis·2023-508275-37-00·Authorised, ongoing·A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)
skipped — LLM skipped (--skip-llm)
- ctis·2024-514345-11-00·Expired·CAPTIRALL _ Combination of an Anti-PD1 antibody with Tisagenlecleucel Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence
skipped — LLM skipped (--skip-llm)
- ctis·2024-512980-29-00·Expired·The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group
skipped — LLM skipped (--skip-llm)
- ctis·2024-514494-21-00·Authorised, ongoing·A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
skipped — LLM skipped (--skip-llm)
- ctis·2023-505627-30-00·Cancelled·An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
skipped — LLM skipped (--skip-llm)
- ctis·2023-507274-40-00·Expired·A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination with Ruxolitinib in Myeloproliferative Neoplasm Subjects, Incorporating Extension Part 6 – Continued Access for Navitoclax to Roll Over Subjects in France and Bulgaria from Studies M16-191 and M20-178
skipped — LLM skipped (--skip-llm)
- ctis·2023-506861-76-00·Expired·A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors ≥ 4 Cm) to Stage IIIa Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
skipped — LLM skipped (--skip-llm)
- ctis·2023-509339-17-00·Cancelled·A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin
skipped — LLM skipped (--skip-llm)
- ctis·2023-508357-58-00·Cancelled·An open-label, first-in-human, dose-escalation/expansion study of SAR443579 administered as single agent by intravenous infusion in adult and pediatric participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Japanese encephalitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Japanese encephalitis" OR "Encephalitis, Japanese" OR "Japanese B encephalitis"
MeSH descriptor terms unioned into the query: Encephalitis, Japanese
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Japanese encephalitis" OR "Encephalitis, Japanese" OR "Japanese B encephalitis"
Interventional trials matched via: both, phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 71 interventional · 7 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (24924) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T02:01:43.248Z